TABLE 3.
Change after normal saline volume load (VL) in tadalafil and SC placebo versus tadalafil and SC BNP
| Variable | Tadalafil + Placebo (n = 20) | Tadalafil + SC BNP (n = 20) | p value |
|---|---|---|---|
| Systolic BP (mmHg) | −7.3 ± 10.6 | −12.4 ± 14.5 | 0.21 |
| Diastolic BP (mmHg) | −5.1 ± 10.6 | −5.4 ± 13.7 | 0.97 |
| Heart rate (bpm) | 1.6 ± 3.7 | 4.3 ± 7.3 | 0.08 |
| LVEF (%) | 1.8 ± 5.6 | 4.1 ± 4.4 | 0.08 |
| LV End Diastolic volume (ml) | 0.5 ± 16.8 | −8.1 ± 15.8 | 0.14 |
| LV End Systolic volume (ml) | −2.3 ± 9.2 | −6.9 ± 9.1 | 0.16 |
| Cardiac output (L/min) | −0.1 ± 0.8 | 0.2 ± 0.7 | 0.25 |
| E/e’ | 0.1 ± 4.6 | −0.7 ± 3.3 | 0.80 |
| RVSP (mmHg) | 2.1 ± 6.0 | −4.0 ± 3.0 | <0.01 |
| LAV (ml) | 2.8 ± 6.6 | −4.3 ± 10.4 | 0.03 |
| ANP (pg/ml) | 3.2 ± 33.5 | −11.8 ± 24.4 | 0.34 |
| BNP (pg/ml) | 5.9 ± 8.5 | 523.8 ± 634.7 | <0.01 |
| cGMP (pmol/ml) | 1.7 ± 3.8 | 11.3 ± 12.3 | <0.01 |
| Aldosterone (ng/dl) | −3.7 ± 9.1 | −3.4 ± 8.2 | 0.50 |
| Angiotensin II (pg/ml) | −0.1 ± 3.0 | 0.0 ± 1.5 | 0.47 |
| GFR (ml/min) | 3.9 ± 24.3 | −5.3 ± 26.1 | 0.14 |
| Renal plasma flow (ml/min) | 13.4 ± 104.0 | −30.7 ± 121.8 | 0.23 |
| Urine flow (ml/min) | 2.1 ± 3.8 | 1.4 ± 3.8 | 0.55 |
| Sodium excretion (mEq/min) | 97.0 ± 182.5 | 92.5 ± 185.0 | 0.90 |
| Urinary cGMP excretion (pmol/min) | 173.4 ± 517.9 | 1851.0 ± 1386.4 | <0.01 |
Values are shown as mean ± SD.
Abbreviations: ANP, atrial natriuretic peptide; BNP, brain natriuretic peptide; BP, blood pressure; cGMP, cyclic guanosine monophosphate; GFR, glomerular filtration rate; LAV, left atrial volume; LVEF, left ventricular ejection fraction; RVSP, right ventricular systolic pressure.